Montreal, Quebec -- December 06, 2018 -- InvestorsHub NewsWire --
Relevium Technologies Inc. (TSX.V:“RLV”,
OTCQB:“RLLVF”
and Frankfurt: “6BX”)
(the “Company”
or
“Relevium”)
is pleased to announce it has retained Rohan Mendonza and his
company, NForce Labs Inc., to lead its Amazon business.
Rohan Mendonza, formerly Director of Operations at Amazon.com Inc.,
is the CEO of NForce Labs, Inc., an e-commerce consulting firm
helping brands streamline supply chains, grow organic marketing,
and optimize paid advertising services with the goal of maximizing
clients’ return on investment. Prior to starting NForce Labs, Rohan
spent nine years with Amazon’s operations team. Rohan graduated
with an undergraduate degree in Mechanical Engineering and worked
for companies including GE Healthcare, and Terumo Medical and has
an MBA from the University of Michigan, Ross School of
Business.
The Amazon Marketplace represents a strategic and important revenue
stream for the company and the addition of NForce to the team is
expected to translate into organic growth, improved new product
adoption, optimized marketing spending and a diversified and
cost-efficient supply chain that is focused on quality ingredients
and innovation.
“We
are very excited to have Mr. Mendonza and the NForce Labs team lead
our Amazon marketplace operations and introduce world-class best
practices to our portfolio of trusted online brands. Mr Mendonza is
an experienced executive and brilliant strategist with an extensive
international network in the nutraceutical business, which will
have a significant impact on our OTC business. We are happy to
welcome him and his team to Relevium” stated Aurelio Useche,
CEO.
About Relevium
Technologies
Relevium is a publicly-traded company that operates in the health
and wellness industry, including legal cannabis, with a primary
focus on online distribution. The principal business of the Company
is the identification, evaluation, acquisition and operations of
brands and businesses in the Health and Wellness markets and
medical cannabis. The Company pursues its business strategy through
an acquisition and partnership model in a holistic approach to
encompass a wide range of health and wellness consumer products.
Relevium operates through two wholly-owned subsidiaries:
BGX E-Health
LLC (BGX): Based in Orlando, Florida, BGX markets dietary
supplements, nutraceuticals, sports nutrition and cosmeceuticals
primarily through its Bioganix® brand portfolio in the US and
Europe. Relevium’s brands such as Bioganix® are
sold at some of the world’s largest retailers including such as
Walmart.com and Amazon.com.
The Company’s strategy for growing its brands includes expanding
its product offering, adding new distribution channels and
developing partnerships that add value through exclusive
ingredients. BGX is currently testing a complete line of dietary
supplements derived from Cannabis with an initial focus on hemp
derived, whole plant organic extract rich in CBD (cannabidiol). The
product line will be marketed through its brand LeefyLyfe® and will
be sold first in Europe and then North America. The Company uses
cannabinoids and ingredients that have achieved GRAS status
(generally accepted as safe) to create brands that are sold via
wholesale channels, retail channels and online distribution.
Biocannabix
Health Corporation (BCX): Based in Montreal, Quebec, BCX
is an entrepreneurial venture to establish a vertically integrated
medical cannabis company in the Nutraceutical space. Located in the
city of Saint Laurent, the Company is in the process of licensing
and retrofitting a facility that will host a genetically focused
cannabis growth, extraction, formulation, research and development
and encapsulation of proprietary Nutraceutical and Medical
products.
Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Cautionary Note
Regarding Forward-Looking Statements
This release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws. All statements in this news
release, other than statements of historical facts, including
statements regarding future estimates, plans, objectives,
assumptions or expectations of future performance, including the
timing and completion of the proposed acquisitions, are
forward-looking statements and contain forward-looking information.
Generally, forward- looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", "would" or "occur". Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including the assumptions that the Company
will be able to apply for and ultimately obtain an ACMPR licence,
the proposed business of Biocannabix will develop as anticipated,
that the Company will raise sufficient funds to develop the
Biocannabix business, and that the Company will obtain all
requisite regulatory approvals. These forward-looking statements
are subject to known and unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward-looking
statements or forward-looking information. Important factors that
may cause actual results to vary, include, without limitation, the
risk that the proposed business developments may not occur as
planned; the timing and receipt of requisite approvals and failure
to raise sufficient funds.
Although management of the Company has attempted to identify
important factors that could cause actual results to differ
materially from those contained in forward-looking statements or
forward-looking information, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can
be no assurance that such statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward- looking statements and
forward-looking information. Readers are cautioned that reliance on
such information may not be appropriate for other purposes. The
Company does not undertake to update any forward-looking statement,
forward-looking information or financial outlook that are
incorporated by reference herein, except in accordance with
applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM
TECHNOLOGIES INC.
Aurelio
Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM
TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us
on Facebook
Follow
us on Twitter
Follow
us on LinkedIn
Relevium Technologies (CE) (USOTC:RLLVF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Relevium Technologies (CE) (USOTC:RLLVF)
Historical Stock Chart
From Sep 2023 to Sep 2024